Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- 14 New Drugs Including Micafungin to Be Included in NHI Price List
December 9, 2002
- Kyorin: New Products Drive Increases in 1st-half Sales, Profits
December 2, 2002
- Azwell: "Painful Reforms" Bring Return to Profitability
December 2, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
December 2, 2002
- Mochida: NHI Price Cuts Affect Semiannual Sales, Profits
December 2, 2002
- Toho: Cost-cutting, Higher Margins Boost Sales, Profits
December 2, 2002
- Meiji Seika Discovers Enzymes Inactivating Abnormal Prion Protein
December 2, 2002
- Rohto: Profits Jump Despite Modest Increase in Sales
December 2, 2002
- Tanabe Seiyaku to Co-develop Altana's Roflumilast
December 2, 2002
- DIAGNOSTIC NEWS IN BRIEF
December 2, 2002
- Kissei: NHI Price Cut, Sluggish Sales Hit Sales, Profits
December 2, 2002
- Nippon Shinyaku's Cylocide Gets New Indication for Malignant Lymphoma
December 2, 2002
- World Self-Medication Industry 14th General Assembly & 5th Asia Pacific Regional Conference
December 2, 2002
- Zeria: Ethical Drug Sales Down 8.9% in First Half
December 2, 2002
- WEBSITE NEWS
December 2, 2002
- WG to Recommend OTC Drugs to Prevent Lifestyle-related Diseases
December 2, 2002
- Fuso: Sales, Profits Down Due to Lower Sales of Dialysis Products
December 2, 2002
- Otsuka's Schizophrenia Treatment Abilify Obtains Approvable Letter from FDA
December 2, 2002
- Sundrug: Strong Sales Support Expansion Beyond Tokyo Metropolitan Area
December 2, 2002
- Wakamoto: Profits Plummet Due to Increased Costs, R&D Investment
December 2, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…